Oct. Thirteen (UPI) — Pfizer and its German partner BioNTech announced Thursday that their Omicron booster shots specifically develop antibody coverage against the BA. 5 subvariant of COVID-19 in initial testing.
The first effects come from blood samples taken from 40 other people over the age of 18 to 55 and another 40 people over the age of 55. Pfizer reports that there has been very extensive development in antibody coverage against the SUBvariant BA. 5 in both groups.
Other data collected from an organization of 40 other people over the age of 55 who had obtained first-generation boosters, but not the specific booster of omicron, indicated only a limited accumulation of BA. 5 antibodies.
The new knowledge is valuable because the Food and Drug Administration approved Omicron boosters in September without human knowledge about how well they would build antibodies opposed to COVID-19’s BA. 5 subvariant.
Pfizer says its Omicron booster is comparable to previous COVID-19 vaccines.